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Neural stem cells (NSCs) and mesenchymal stem cells (MSCs) share few characteristics
apart from self-renewal and multipotency. In fact, the neurogenic and osteogenic
stem cell niches derive from two distinct embryonary structures; while the later
originates from the mesoderm, as all the connective tissues do, the first derives
from the ectoderm. Therefore, it is highly unlikely that stem cells isolated from one
niche could form terminally differentiated cells from the other. Additionally, these two
niches are associated to tissues/systems (e.g., bone and central nervous system) that
have markedly different needs and display diverse functions within the human body.
Nevertheless they do share common features. For instance, the differentiation of both
NSCs and MSCs is intimately associated with the bone morphogenetic protein family.
Moreover, both NSCs and MSCs secrete a panel of common growth factors, such as
nerve growth factor (NGF), glial derived neurotrophic factor (GDNF), and brain derived
neurotrophic factor (BDNF), among others. But it is not the features they share but the
interaction between them that seem most important, and worth exploring; namely, it has
already been shown that there are mutually beneficially effects when these cell types
are co-cultured in vitro. In fact the use of MSCs, and their secretome, become a strong
candidate to be used as a therapeutic tool for CNS applications, namely by triggering
the endogenous proliferation and differentiation of neural progenitors, among other
mechanisms. Quite interestingly it was recently revealed that MSCs could be found in
the human brain, in the vicinity of capillaries. In the present review we highlight how
MSCs and NSCs in the neurogenic niches interact. Furthermore, we propose directions
on this field and explore the future therapeutic possibilities that may arise from the
combination/interaction of MSCs and NSCs.
Keywords: mesenchymal stem cells, neural stem cells, niche, neurogenesis, secretome, regenerative medicine,
interactions
Introduction
Injury and disease within the central nervous system (CNS) frequently induce chronic
and acute insults leading to irreversible processes of neuronal cell death. Understanding
how neurogenesis can be modulated, either through drugs or interaction with other
cell types, and neural progenitors recruited to the site of injury, is of the utmost
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importance for the development of novel strategies that may
impact the current state of the art. In recent years it has become
evident that a population with a non-neural phenotype known
for their role in the osteogenic niche, mesenchymal stem
cells (MSCs), is able to regulate important phenomena within
the CNS, including neural progenitor cells proliferation and
differentiation. This quite unexpected and surprising function
of MSCs brought closer the neurogenic and osteogenic niches,
and prompted a new field of research that aims at understanding
their interaction, and how both may impact on CNS regenerative
medicine as we know it. Having this in mind the objective of
the present paper is to review the most relevant advances in
this field. It will first give an overview of neurogenic niches
and how neurogenesis is regulated within them, then give an
introduction to the osteogenic niches and MSCs, and end with
a review on the most important works on the interactions
between MSCs, neurogenic niches and disease models
within the CNS.
Neurogenesis in the Adult Brain
Neuroanatomists have long believed Cajal’s assumptions on the
immutability of the CNS. This dogma has been challenged due
to growing evidence that endow the brain with considerable
regenerative potential and neuroplastic capacity, essential to
promote brain homeostasis (Lemaire et al., 2012). It is now well
established that adult neurogenesis occurs throughout life in
specific brain regions where neurons are constantly generated
(Doetsch et al., 1999; Gage, 2002).
Globally, this neuroadaptative phenomenon occurs by the re-
organization of the neuromorphological and electrophysiological
properties of post-mitotic cells and the generation of new
neuronal or glial cells that will incorporate the pre-existing
networks, a process therefore called neuro- or gliogenesis,
respectively (Guan et al., 2009). This complex process involves
several steps beyond cell division; these include the commitment
of the new cell to a neuronal phenotype, the migration and
morphophysiological maturation of the neuroblasts, and the
establishment of appropriate synaptic contacts that culminate
with a full integration on the pre-existent network. These
spatially defined brain regions where neurogenesis occurs display
a permissive microenvironment for maintenance, proliferation
and differentiation of Neural stem cells (NSCs). Admittedly,
at least two defined neurogenic brain regions are broadly
recognized in the adult mammalian brain (Figure 1): the
subependymal zone (SEZ) of the lateral ventricles, and the
subgranular zone (SGZ) of the hippocampal dentate gyrus (DG;
Zhao et al., 2008). In both regions, astroglial cells act as the source
of adult progenitor cells (Seri et al., 2001).
In the adult hippocampal neurogenic region, the progenitor
cells reside in the SGZ, with defined gradients (Silva et al., 2006).
Newly-born cells generated in the SGZ, become committed to
a neuronal lineage and migrate into the granular cell layer
(GCL), where they mature to become glutamatergic granule
neurons (Seri et al., 2004; Zhao et al., 2008; Brill et al., 2009).
The neuroblasts born in the SEZ migrate anteriorly along
the rostral migratory stream (RMS), becoming mostly mature
GABAergic granule neurons and periglomerular interneurons
in the olfactory bulb (OB; Chumley et al., 2007; Zhao et al.,
2008). Besides these two well-accepted adult neurogenic regions,
although disputable, some reports have shown evidences for
the generation of new neurons on other brain regions of
the adult brain, including the amygdala (Bernier et al., 2002;
Fowler et al., 2005; Gonçalves et al., 2008), the hypothalamus
(Fowler et al., 2002; Kokoeva et al., 2005), the cortex (Gould
et al., 1999; Kodama et al., 2004), the striatum (Dayer et al.,
2005; Bédard et al., 2006) and the substantia nigra (SN; Zhao
et al., 2003; Yoshimi et al., 2005). Importantly, it appears that
neurogenesis in these regions occurs at very low levels or
under non-physiological conditions (von Bohlen und Halbach,
2011).
Importantly, the neurogenesis process in the adult brain
constitutes a new dimension of plasticity, with great impact
on neuronal remodeling and repair, being now considered
by the biomedical field as a promising therapeutical target
in several neuropathological contexts. For instance, abnormal
alterations in the hippocampal neurogenesis process have been
implicated in an assortment of neuropsychiatric disorders
(Sapolsky, 2000; Eisch et al., 2008; Kobayashi, 2009). Indeed,
impairments in neuroplasticity are increasingly considered
central to the ethiopathogenesis of depression (Bessa et al.,
2009; Mateus-Pinheiro et al., 2013a,b). Studies have also
shown the contribution of new neurons to a subset of
hippocampal functions, influencing mood control, learning
and memory (Hanson et al., 2011; Eisch and Petrik, 2012;
Konefal et al., 2013). In fact, a clear connection between
adult neurogenesis and learning/memory was demonstrated,
as diminished neurogenesis decreases learning/memory, while
enhanced neurogenesis improves it (Eisch and Petrik, 2012;
Nakashiba et al., 2012). These examples prompt for the relevance
of modulating the neurogenic niches as a potential therapeutic
strategy to treat the symptoms of neurodegenerative disorders
such as Parkinson’s disease (PD), which we will later develop in
the context of MSCs derived therapies.
We will next refer to the structural and functional
organization specificities of the adult SGZ and SEZ neurogenic
niches.
Adult Hippocampal Neurogenesis
As referred above, the adult brain is capable of generating new
cells that can incorporate into its established complex circuitry
(Trujillo et al., 2009). This process of adult neurogenesis
highly recapitulates the embryonic neurogenic process, with
the important difference that new neurons are generated
in an already mature microenvironment and have to
integrate in pre-existing neural circuits. Adult hippocampal
neurogenesis consists of several highly regulated sequential
phases (Kempermann et al., 2004; Ming and Song, 2005)
characterized by morphological distinct cells: (i) proliferation
of neural progenitor cells residing in a narrow layer of about
three nuclei wide, the SGZ; (ii) generation of amplifying
progenitors; (iii) cell migration; (iv) differentiation; and
(v) maturation at the final destination with axon and
dendrites formation and establishment of new synapses
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FIGURE 1 | Neurogenic niches in the adult brain. The top panel represents,
in a saggital section of the rodent brain, the two major niches of neural
progenitor cells in the adult brain: one, in the sub granular zone of the dentate
gyrus (DG) of the hippocampus, and the other, the subependymal zone (SEZ),
from where progenitor cells committed to the neuronal lineage migrate via the
rostral migratory stream (RMS) towards the olfactory bulb (OB). The bottom left
panel illustrates the typical cytoarchitecture of the SEZ niche while the cell
population in the DG niche is presented in the bottom right panel.
(Kempermann et al., 2004; Steiner et al., 2006; Balu and Lucki,
2009).
The adult SGZ contains heterogeneous progenitor cells,
which can be distinguished and identified by a particular set
of molecules expressed by each progenitor population. The
first type of progenitors are the quiescent neural progenitors
(QNPs), described to be multipotent stem cells (Seri et al.,
2001, 2004) and also known as NSCs or type-1 progenitor cells
(Type-1 cells). These cells have morphological and antigenic
glial properties, expressing markers such as the intermediate
filament protein nestin, brain lipid binding-protein (BLPB),
the glutamate aspartate transporter (GLAST; Steiner et al.,
2006) and glial fibrillary acidic protein (GFAP), among others;
it can be further distinguishable into two subtypes, based
on their spatial orientation in the SGZ: radial astrocytes
(rA) and horizontal astrocytes (hA). Radial astrocytes are
characterized by having a single radial process, being also
slowly dividing cells, whereas hA present a short horizontal
process and divide faster (Lugert et al., 2010; Hodge et al.,
2012). These cells divide asymmetrically giving rise to transient
amplifying neural progenitors (tANPs, also designated as type-
2 progenitor cells or TAPs). It is important to notice that this
phase of the neurogenic process comprises a decisive point
in the determination of neural progenitors cell-fate (neuronal
or non-neuronal lineage commitment; Steiner et al., 2006).
This latter progenitor cells, TAPs, are already committed to
a neuronal lineage, being mitotically active (Encinas et al.,
2006) and dividing symmetrically to give rise to neuroblasts
(also known as type-3 cells). Neuroblasts are intermediate
progenitors in the generation of new glutamatergic granule
neurons, corresponding to a stage of transition from a slowly
proliferating neuroblast, which is exiting the cell cycle, to
a postmitotic immature neuron, that will migrate into the
GCL of the DG. These neuroblasts express markers of the
neuronal lineage, such as the polysialylated-neural cell adhesion
molecule (PSA-NCAM), calcium-binding protein calretinin
and doublecortin (DCX), that are crucial for further maturation
and migration of these cells (Pleasure et al., 2000; Ehninger
and Kempermann, 2003; Balu and Lucki, 2009). When reaching
the GCL, newborn cells will fully maturate, elongating their
axons towards the CA3 region (von Bohlen und Halbach,
2011) and establishing new functional connections (Balu and
Lucki, 2009), thus becoming mature granule neurons, which
express neuronal nuclei protein (NeuN). The cell markers
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described above are not all exclusive to the SGZ; as will
be described next, some are also characteristic of cells from
the SEZ niche (Table 1). Moreover, similarly to the SEZ,
only some of these markers allow cell-specific phenotypic
characterization, as indicated in Table 1. Approximately 2–3
weeks after exiting the cell cycle, they express calbindin, a
marker of mature granule cells (Kempermann et al., 2004). Newly
formed neurons enter a period of enhanced synaptic plasticity
in which their electrophysiological properties resemble those
of neurons in the early postnatal period in juvenile animals
(Ge et al., 2007). This phase lasts around 4–6 weeks after
the original cell division, resulting in a total of approximately
7–8 weeks required for newborn cells to become functionally
indistinguishable from the older granule cell population (Carlén
et al., 2002; Abrous et al., 2005; Zhao et al., 2008; Snyder
et al., 2009; Hanson et al., 2011). Newborn neurons display very
different characteristics than mature ones, such as enhanced
excitability, reduced threshold to induction of long-term
potentiation (LTP) and an excitatory response to GABAergic
input, since this neurotransmitter induces depolarization instead
of hyperpolarization that is seen in adult neurons, which is
related to a specific pattern of expression of some ionic co-
transporters. This clearly indicates that adult-born neurons
possess specific properties associated with plasticity (Schmidt-
Hieber et al., 2004; Saxe et al., 2006; Ge et al., 2007; Hanson et al.,
2011).
Noticeably, neurogenesis is a fine tuned process, in which not
all cells expressing immature neuronal markers develop into fully
mature neurons (Kempermann et al., 2003) and most newly-
born neurons are eliminated by apoptosis (Biebl et al., 2000).
The mechanisms that regulate this clearance of neurons are still
to be fully understood, however, very recently a report showed
that DCX-neuronal progenitors present phagocytic activity in the
hippocampal and SEZ neurogenic niches and have great impact
in the neurogenic process (Lu et al., 2011).
The harmonization of the several processes and cellular
activities that occurs during the generation of new neurons in
the adult mammalian brain is thus paramount. Several studies
propose a complex transcriptional and epigenetic orchestration
of the adult hippocampal neurogenic process, with both intrinsic
and extrinsic factors being ultimately responsible for the
modulation of this phenomenon. Therefore, the niche, where
adult neurogenesis occurs is also crucial for the modulation and
fine-tuning of this process.
Subependymal Zone Neurogenesis
The SEZ, also referred in the literature as adult subventricular
zone (SVZ), is the site of the adult brain where neurogenesis
is most intense. In rodents, the SEZ is seldom described as
a thin layer of cells located below the ependymal layer that
lines the lateral walls of the lateral ventricles, but it also
extends to the dorsal and medial ventricular walls (Alvarez-
Buylla et al., 2008). As in the SGZ niche, the cell populations
in the SEZ are heterogeneous, containing several cell types that
are identifiable by cell-specific markers. In general terms it might
be described as being composed of slow-dividing type B cells
(the NSCs) that originate fast-dividing type C cells, that in
turn give rise to neuroblasts (type A cells). Nevertheless, given
the complexity of these cell populations they, and respective
phenotypic markers, will next be described with further detail
(see also Table 1).
Type B cells are astrocytic cells and express the intermediate
filament GFAP. In the SEZ two types of GFAP positive cells
were distinguished according to ultrastructural differences: type
B2 astrocytes, or niche astrocytes, display a highly branched
morphology and are frequently found in the interface of the
SEZ and the striatum (Doetsch et al., 1997); type B1 astrocytes
are radial-glia like that organize in pinwheel structures with
the apical ending, the primary cilium, turned towards the brain
ventricles—and hence in bathed in the cerebrospinal fluid—and
is surrounded by ependymal cells (Mirzadeh et al., 2008). The
type B1 cells are recognized as the NSCs of the SEZ. Type C
cells, or TAPs, originate from the NSCs. These rapidly dividing
cells are organized in clusters of immature precursors that
express distal-less homeobox 2 (Dlx2), achaete-scute complex
homolog 1 (Ascl1or Mash1) and epidermal growth factor
TABLE 1 | Summary of markers that specifically allow phenotypic characterization of major cell types found in both neurogenic and osteogenic niches.
Type-1 (NSCs) Type-2 (TAPs) Type-3 (Neuroblasts) Mature neurons
Neurogenic niches SGZ GFAP Mash1 DCX NeuN
GLAST Tbr2 PSA-NCAM
Ngn2
Type B (NSCs) Type C (TAPs) Type A (Neuroblasts) Mature neurons
SEZ GFAP Mash1 DCX NeuN




Osteogenic niches Osteoblasts Runx-2; OCN; OPN; ON; ALP
MSCs Positive for CD105, CD73, CD90 Negative for CD45, CD34, CD14, CD11b, CD79a, CD19
SGZ, subgranular zone; SEZ, subependymal zone; NSCs, neural stem cells; TAPs, transient amplifying progenitors; GFAP, glial fibrillary acidic protein; GLAST, glutamate
aspartate transporter; Mash1, mammalian achaete-scute complex homolog 1; Tbr2, T-box brain 2; Ngn2, neurogenin 2; DCX, doublecortin; PSA-NCAM, polysialylated-
neural cell adhesion molecule; NeuN, neuronal nuclei; Dlx2, distal-less homeobox 2; GAD65, glutamate decarboxylase 65; TH, tyrosine hydroxylase; OCN, osteocalcin;
OPN, osteopontin; ON, osteonectin; ALP, alkaline phosphatase.
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receptor (EFGR; Ciccolini et al., 2005; Ming and Song, 2011).
A short pulse (24 h) of the timidine analog BrdU mainly
labels TAPs indicating that these cells are the largest pool of
proliferating cells in the SEZ. Type A cells, or neuroblasts, are
born from type C cells and constitute the neuronal precursors
cells. Most type A cells express PSA-NCAM and DCX, which are
associated to their migratory properties (Ming and Song, 2011).
Under physiological conditions neuroblasts migrate tangentially
from the SEZ, via the RMS to the OBs where they become
fully mature neurons. Neuroblasts divide actively in the SEZ
but also in the RMS. Once in the OBs, neuroblasts migrate
radially, give rise to mature neurons and are integrated in
distinct layers of the OB. They form new granular cells
(deep, superficial and calretin positive) and periglomerular cells
(calretin positive, calbidin positive and tyrosine hydroxylase
positive; Lledo et al., 2008; Kriegstein and Alvarez-Buylla,
2009). Most of these new neurons are granule cells integrated
in the granule cell layer and are GABAergic, but a small
group of glutamatergic neurons was also identified (Brill et al.,
2009).
Also of relevance in the SEZ are the ependymal cells (type E
cells) that, as indicated above, form a monolayer that outlines
the ventricular wall. These cells constitute a physical barrier that
diminishes the direct and free exchange of molecules between the
CSF and brain parenchyma (Falcão et al., 2012a). Two distinct
ependymal cells have been described: the most common type E1
ependymal cells that aremulticiliated, and the E2 ependymal cells
that display two long cilia and represent solely 5% of the type
E cells (Mirzadeh et al., 2008). Under physiological conditions
these cells proliferate rarely (Coskun et al., 2008) or do not
proliferate at all (Mirzadeh et al., 2008).
Tanycytes (Doetsch et al., 1997; Chojnacki et al., 2009),
microglia (in response to injury; Ekdahl et al., 2009) and
endothelial cells of the blood vessels (Tavazoie et al., 2008)
are also relevant cellular components of the SEZ niche. These
later cell types contribute to the specific microenvironment
that constitute the SEZ NSCs niche; for instance, endothelial
cells secrete several factors (pigment epithelium-derived factor,
PEDF; NT3, among others) that induce proliferation and
migration of NSCs (Ramírez-Castillejo et al., 2006; Delgado
et al., 2014). Hence their interaction with proliferating
cells should be taken into account when considering the
modulation of the SEZ NSCs namely if one targets, for
neuroregenerative purposes, the application of exogenous cells
and/or protein/molecular factors, as will be further discussed in
later sections.
In addition to the SEZ cellular heterogeneity, there is
a further level of complexity in the form of topographical
heterogeneity. A simple observation on the topography of
the SEZ discloses major anatomical differences (Falcão et al.,
2012b). It is now evident that even in the above described
cell populations lays a remarkable heterogeneity either due
to inherited intrinsic or epigenetic factors (Alvarez-Buylla
et al., 2008) and/or an additional diversity in the surrounding
microenvironment cues. Several studies showed that the
NSCs pool is highly heterogeneous both in the origin and
in cellular fate (Merkle et al., 2007; Alvarez-Buylla et al.,
2008). For instance, while the common fate of SEZ born
cells is the OB where they become interneurons, it was
shown that it also generates a small pool of glutamatergic
neurons steming from NSCs that reside in the adult dorsal
wall of the lateral (Brill et al., 2009). Moreover, neuroblasts
born either in ventral, dorsal, anterior or posterior regions
are distinct, produce different neuronal types and are
integrated in different layers of the OB (Alvarez-Buylla
et al., 2008). As an example, neuroblasts from dorsal
regions mostly originate superficial granule cells; while
ventral derived neuroblasts give rise mostly to deep granule
cells (Merkle et al., 2007). Also of notice, SEZ NSCs also
originate oligodendrocyte precursors that migrate to the
striatum and the corpus callosum and differentiate into
oligodendrocytes (Nait-Oumesmar et al., 1999; Picard-
Riera et al., 2002). The reason for why different regionally
placed NSCs give rise to distinct progeny might reside in
the distribution pattern of specific transcription factors,
adding another layer of complexity in the regulation of cell
proliferation in the SEZ, and thus in cell fate. All of these
cell intrinsic and extrinsic aspects must be taken into account
when considering putative therapeutic approaches for CNS
regeneration.
Transcriptional Regulation of Adult Neurogenesis
Adult neurogenesis gives rise to both glutamatergic and
GABAergic neurons. In the hippocampus changes in
the rates of generation of glutamatergic neurons might
contribute to several pathologies. In this context, the
discovery of new factors important for the generation
of glutamatergic neurons is needed. Interestingly, adult
glutamatergic neurogenesis recapitulates the sequential
expression of transcription factors found in the developing
cerebral cortex (Pax6→Neurogenin2→Tbr2→Tbr1),
demonstrating that this transcription network is maintained
postnatally (Brill et al., 2009). For example, Pax6, a crucial
determinant for the specification of glutamatergic neurons
during development, is essential for adult neurogenesis
(Hack et al., 2005) and is sufficient to instruct postnatal
neocortical astrocytes towards neurogenesis in vitro (Heins
et al., 2002). It was also shown during development, that one
of the downstream targets of Pax6, the transcription factor
AP2γ, is important for the specification of glutamatergic
neocortical neurons and their progenitors (Pinto et al.,
2009), and also for the differentiation of glutamatergic
neurons in the adult neurogenic regions. Furthermore,
AP2γ regulates Tbr2, which was shown to be important for
glutamatergic neurogenesis during development (Pinto et al.,
2009).
As described above, generation of specific cell types (neuronal
or glial type) in the adult SEZ is topographically heterogeneous
and this might be bound to transcriptional regulation. In fact, the
expression of distinct transcription factors in both overlapping
and non-overlapping regions of the SEZ is described. Similarly
to the SGZ, some of these transcription factors were correlated
with the SEZ embryonic origin (Waclaw et al., 2006; Young
et al., 2007). In fact, a topographical pattern of transcription
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factors expression in the SEZ is associated with NSCs embryonic
origin and adult neuronal fate. Generally, NSCs in the lateral
ventricular wall ubiquitously express Dlx1, 2, 5 and Mash1,
while Emx1 expression is exclusive to the dorsal wall of the
ventricle (Young et al., 2007). Furthermore, the transcription
factors Nkx2.1 and Pax6 outline the ventral and dorsal regions
of the lateral wall, respectively (Alvarez-Buylla et al., 2008;
Weinandy et al., 2011). Thus, in the SEZ, an additional challenge
is to understand how to modulate different combinations of
transcription factors so as to result in production of specific
neuronal types.
A targeted induction of neurogenesis, by stimulating
endogenous neural progenitors in the adult brain,
could represent an important cellular therapy to treat
neurodegenerative disorders. A major challenge in our
days is to improve survival and induce differentiation of
newborn neurons after acute lesions. For instance, it was
already shown that Pax6 can induce neurogenesis from
non-neurogenic astrocytes in vivo, when overexpressed after
stab-wound lesion (Buffo et al., 2005). These experiments
provide proof of principle that neurons can be newly generated
from endogenous sources of the adult mammalian brain.
However, these induced neurons are very few in number
and fail to mature. Therefore, new cues are needed to
efficiently instruct neurogenesis and repair after neuronal
insult.
The Microenvironment of the Neurogenic Niches
The interplay between extrinsic and intrinsic factors determines
the NSCs niche homeostasis. Intrinsic factors are a set
of signals produced by the progenitors that together with
exterior microenvironment cues (extrinsic factors) instruct
distinct neurogenic phases and ultimately the cellular fate.
Many of the mechanisms regulating NSCs proliferation and
neurogenesis during embryonic development, appear to be
conserved in adulthood, and both intrinsic and extrinsic factors
important for embryonic neurogenesis are also involved in
the regulation of neurogenesis in the adult brain (Ming and
Song, 2011). However, there are relevant differences between
them, especially regarding the properties of the cellular and
molecular niche. Whereas during development, the cellular
environment is highly specialized to support proliferation,
in the adult neurogenic niches the environmental context
is concomitantly able to maintain a population of fully
mature neurons (Zhao et al., 2008; Jessberger et al., 2009),
thus providing a different set of both intrinsic and extrinsic
signals.
Extrinsic signals, for instance, for the SEZ regulation
include several trophic and growth factors, neurotransmitters,
morphogens, hormones and cytokines (Falcão et al., 2012a).
These extracellular signaling molecules are of diverse origins,
namely from ependymal cells, endothelial cells, neural progenitor
cells and neurons. The neurotransmitters are examples of
key extrinsic factors of neuronal origin. For instance, the
neurotransmitter GABA produced by niche neuroblasts is
reported to inhibit NSCs proliferation but serotonine stimulates
NSCs proliferation (Banasr et al., 2004, and conflicting results
were presented for the effects of dopamine (DA) in the SEZ niche
(Berg et al., 2013).
This important role of the microenvironment in the
neurogenic niches for the regulation of NSCs has been shown
by many in vivo and in vitro studies. For example, SEZ
derived neuroblasts can change their fate and differentiate
into oligodendrocytes upon a change in the microenvironment
induced by demyelination of the corpus callosum (Picard-
Riera et al., 2002; Jablonska et al., 2010). Additionally, glial
progenitor cells may change to a neuronal fate when transplanted
into a neurogenic region (Shihabuddin et al., 2000), while
mouse SEZ neural progenitors committed to the neuronal
lineage, changed to glial differentiation upon transplantation
into regions outside the neurogenic niche (Seidenfaden et al.,
2006).
The microenvironment of the neurogenic niches is thus
essential for fate determination and cell differentiation, as well
as for self-renewal, proliferation, migration and maturation
of NSCs. This microenvironment is comprised of local cell
types, cell signals, extracellular matrix and microvasculature.
Indeed, the SEZ and SGZ niches are highly vascularized by
a network of specialized capillaries (Goldberg and Hirschi,
2009) and NSCs closely interact with the microvasculature
(Palmer et al., 2000; Mirzadeh et al., 2008; Shen et al., 2008;
Tavazoie et al., 2008). This microvasculature has been shown
to be essential in maintaining the function of the neurogenic
niches, namely by regulating the proliferation and quiescence
of NSCs (Palmer et al., 2000; Shen et al., 2004, 2008; Tavazoie
et al., 2008; Culver et al., 2013), as well as NSCs self-renewal
and neurogenesis through soluble factors secreted by the
endothelial cells (Shen et al., 2004; Ramírez-Castillejo et al.,
2006; Gómez-Gaviro et al., 2012). Noteworthy is the recent
report of the existence of MSCs in the brain microvasculature
(Paul et al., 2012), which paves way for the usage of MSCs
secretome to modulate the neurogenic niches cells. One further
example of NSCs microenvironment modulators are microglia
cells, the brain resident macrophages, have also a crucial role
in the regulation and maintenance of neurogenesis in the
SGZ neurogenic niche (Sierra et al., 2010) given that they
impact on the proliferation of neural stem/progenitor cells
(Gebara et al., 2013); also they are particularly relevant in
modulating the SEZ in response to brain injury (Thored et al.,
2009).
In this way, signaling from and into the niche is suggested to
be responsible for key processes in the regulation of homeostasis
of adult neurogenesis including the balance between quiescence
vs. proliferation, the mode of cell division, and the prevention of
stem cell depletion.
The existence of NSCs in the adult neurogenic niches
prompted research for their usage in adult brain regeneration.
Nevertheless, their intrinsic and extrinsinc properties, which
we have summarized above, pose also major challenges to
mount adequate therapeutic approaches. MSCs, and specifically
the interaction of their properties with NSCs, might be ideal
candidates for this purpose. We will next describe the major
characteristics of MSCs and how they might promote brain
regeneration.
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The Osteogenic Niche
The osteogenic niche is a highly vascularized and dynamic
environment in which four cell types play an important role on
the maintenance and renewal of bone tissue: MSCs, osteoblasts,
osteocytes and osteoclasts.
Osteoblasts (Table 1) arise from osteoprogenitor and MSCs
(further details on MSCs biology are discussed in ‘‘MSCs and
CNS Therapies’’ Section) present in the bone marrow and
periosteum. They are known to be involved in the synthesis
and regulation of extracellular matrix elaboration (ECM) and
mineralization (Sommerfeldt and Rubin, 2001; Salgado et al.,
2004). Furthermore, it is also known that basic cellular
functions and responsiveness to metabolic and mechanical
stimuli demand are maintained through extensive cell-matrix
and cell-cell contacts via a variety of transmembranous
proteins and specific receptors (Sommerfeldt and Rubin, 2001).
Osteocytes represent osteoblasts that became incorporated in the
newly elaborated extracellular matrix, being enclosed in spaces
called lacunae. They maintain direct contact with neighboring
osteocytes, osteoblasts and bone lining cells through cellular
processes that are created before and during matrix synthesis
(Sommerfeldt and Rubin, 2001; Knothe et al., 2004). In mature
bone these cell processes are contained in channels called
the canaliculi. The communication and interaction between
neighboring osteocytes is achieved through the establishment
of gap junctions (Sommerfeldt and Rubin, 2001; Knothe
et al., 2004). This is an absolute need for osteocytes because
is the only way by which they can assure the access to
oxygen and nutrients. They are known to be involved in the
calcification of osteoid matrix, blood-calcium homeostasis and
to be the mechanosensor cells of bone (Sikavitsas et al., 2001;
Knothe et al., 2004). Finally, osteoclasts, are multinucleated
polarized cells involved in the bone remodeling process,
that belong to the monocyte/macrophage lineage. Their main
function is to resorb mineralised bone. For this purpose they
are enriched in intracellular structures such as pleomorphic
mithocondria, vacuoles, and lysossomes, as well as alterations,
namely at the structural level, in its cell membrane (Vaananen,
1996).
Mesenchymal Stem Cells
Mesenchymal Stem Cells, The Secretome and
Neurogenic Niches
The first reports on the possible existence of a population with a
Mesenchymal progenitor character are attributed to Friedenstein
et al. (1974b). Indeed, Friedenstein et al. identified and defined
these cells as plastic-adherent fibroblast colony-forming units
with clonogenic capacity (Friedenstein et al., 1974a). Later,
these cells were also named as marrow ‘‘stromal cells’’, on the
basis of their possible use as a feeder layer for hematopoietic
stem cells (Eaves et al., 1991; Glavaski-Joksimovic and Bohn,
2013). Additionally other reports also referred to them as MSCs
because of their clonogenicity capacity and ability to undergo
multilineage differentiation (Caplan, 1991; Bluguermann et al.,
2013). Currently MSCs have been defined, according with the
International Society for Cellular Therapy (ISCT) criteria, as
multipotent cells (with the ability of at least differentiating
towards the osteogenic, chondrogenic and adipogenic lineages),
capable of self-renewal, able to adhere to tissue culture plastic
and to display the presence of surface markers (CD105, CD73,
CD90), as well as the lack of hematopoietic cell surface markers
(CD45, CD34, CD14 or CD11b, CD79a or CD19 and Human
Leukocyte Antigen DR; Table 1; Dominici et al., 2006). So far,
MSCs have been isolated from bone marrow (BMSCs), adipose
tissue (ASCs), dental pulp, placenta, amniotic fluid, umbilical
cord blood, umbilical cord Wharton’s jelly (bulk—WJ-MSCs;
perivascular region—human umbilical cord perivascular cells,
HUCPVCs), liver, lung and spleen, and brain (for an extensive
review see Teixeira et al., 2013). As potential therapeutic
agents, MSCs display a number of key characteristics that
are believed to be advantageous when compared to other cell
populations. For instance they can be isolated with minimal
invasive procedures, easily cultured and expanded in vitro for
several passages, can be used for allogenous transplantation
in virtue of their hypoimmunogenicity, decreased tumorigenic
potential and, as adult cells, are not hindered by ethical
concerns (Salgado et al., 2006; Kishk and Abokrysha, 2011; Seo
and Cho, 2012; Teixeira et al., 2013). These MSCs features
have made them attractive tools for CNS neurodegenerative
diseases.
Initially it was considered that the true therapeutic potential
of these cells relied on their multilineage differentiation. Indeed
most of the literature of the 90 s and early 21st century was
focused on the differentiation of these cells towards mesodermal
lineages, such as the osteogenic, mainly within 3D matrices
known as scaffolds, to induce regeneration in the affected areas.
Around the same time it was also suggested thatMSCs even had a
greater differentiation potential than was originally predicted, as
several reports indicated that these cells could be differentiated
beyond the mesodermal lineages (Dominici et al., 2006). In 2005,
Gnecchi et al. (2005) put forward a new concept that lately would
change the paradigm of howMSCs could be used in regenerative
medicine, by showing that their therapeutic potential was mostly
related to the growth factors that they secreted to the extracellular
milieu, rather than to their differentiation potential.
Indeed, in recent years it is becoming increasingly accepted
that the regenerative effects promoted by MSCs are mainly
associated with their secretome. As discussed by Teixeira et al.
(Teixeira et al., 2013) the secretome of MSCs is composed by
a proteic soluble fraction, constituted by growth factors and
cytokines, and a vesicular fraction composed by microvesicles
and exosomes, which are involved in the transference of proteins
and genetic material (e.g., miRNA) to other cells. The protective
actions promoted by MSCs secreted molecules are closely related
with therapeutic plasticity in the CNS. Indeed several authors
have reported the presence of a plethora of growth factors
with a known influence on neuronal survival, differentiation,
neurite outgrowth and immunomodulation of microglial cells;
these factors are BDNF, glial derived neurotrophic factor
(GDNF), nerve growth factor (NGF), hepatocyte growth factor
(HGF), vascular endothelial growth factor (VEGF), VEGF-
receptor 3 (VEGF-R3), angiopoietin 1, insulin-like growth factor
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1 (IGF-1), insulin-like growth factor 2 (IGF-2), epidermal
growth facto (EGF), basic fibroblast growth factor (bFGF),
FGF 20, granulocyte colony-stimulating factor (G-CSF), platelet-
derived growth factor AA (PDGF-AA), chemokine ligand
16 (CXCL 16), neutrophil-activating-protein-2 (NAP 2) and
neurotrophin-3 (NT-3) growth factors, as well as interleukin-
6 (IL-6), interleukin-10 (IL-10), transforming growth factor
beta 1 (TGF β1), stem cell factor (SCF), stromal cell-derived
factor 1 (SDF-1) and monocyte chemotactic protein 1 (MCP-
1) cytokines (Rehman et al., 2004; Caplan and Dennis, 2006;
Chen et al., 2008b; Bonfield et al., 2010; Meyerrose et al., 2010;
Nakano et al., 2010; Ribeiro et al., 2012). Other proteins such
as 14-3-3, ubiquitin carboxyl-terminal esterase L1 (UCHL1),
hsp70 and peroxiredoxin-6 have also been related to the
neuroregulatory character of the secretome of MSCs (Fraga et al.,
2013).
The action of MSCs and their secretome in neurogenic niches
(Figure 2) such as the SGZ has been previously described.
For instance, Munoz et al. (2006) transplanted BMSCs into
the DG of immunodeficient mice. Results revealed that the
transplanted MSCs markedly increased the proliferation of
endogenous NSCs that expressed the stem cell marker Sox2,
as well as their differentiation, a fact that was attributed to
a local increase on the expression of growth factors such as
VEGF, ciliary neurotrophic factor (CNTF), neurotrophin-4/5
and NGF. More recently it was also shown that the injection
of the secretome of MSCs itself, was also able to modulate
both neuronal survival and differentiation within the adult rat
hippocampus. Teixeira et al. (2015) show that the injection of
the secretome of HUCPVCs (a MSC population that resides
in the perivascular region of the umbilical cord) was able to
induce an increased number of DCX+ cells. This observation was
then related with a higher expression of FGF-2 and NGF in the
injected area.
As a consequence of this, the multiple faces of MSCs
and their secretome have prompted a number of different
experimental therapeutic strategies in CNS regenerative
medicine. Such strategies rely on a strong interplay between
neuroregulatory molecules secreted by MSCs and the different
niches with the CNS.
In disorders such as multiple sclerosis (MS), available
data, both from animal models and human patient related
FIGURE 2 | Interaction between mesenchymal stem cells (MSCs) and
neurogenic niches. MSCs, a cell population with a known function in the
osteogenic niche, is able to modulate the action of Neural stem cells (NSCs) by
means of their secretome. Through the secretion of neuroregulatory molecules,
either soluble or in the form of vesicles, MSCs are able to influence processes
such as neurogenesis, gliogenesis, remyelination and neural plasticity. With it
important developments have been recently witnessed in CNS regenerative
medicine strategies.
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studies, indicates that the immunomodulatory properties of the
secretome of MSCs regulate the immune/oligodendrogenic
niches. For instance Wang et al. (2010) revealed that
MSCs derived from human embryonic stem cells (hES-
MSCs) significantly reduce clinical symptoms and
prevent neuronal demyelination in a mouse experimental
autoimmune encephalitis (EAE) mouse model of MS,
by reducing the frequency of CD4+ and CD8+ cells
infiltration in the CNS. A similar trend was described
by Li et al. (2014) and Llufriu et al. (2014) in studies
with human patients, in which the administration of
MSCs from different sources, alone or combined with
pharmacotherapies, positively impacted the condition
of the patients, by modulating MS related inflammatory
events.
On other hand, in disorders such as PD, Ischemic Stroke (IS)
andGlioblastomaMultiforme (GBM) it is believed that the action
ofMSCs goes beyond the neuro-immunomodulation, and in fact,
some of the reported benefits may be closely related with their
direct interaction with the neurogenic niches. Due to the nature
and objectives of this review, this topic will be further explored in
the following section.
MSCs and CNS Therapies
Parkinson’s Disease
Among CNS disorders, PD is the most common motor-
related disorder in middle or late-life affecting millions
(Pereira and Aziz, 2006) worldwide. It is a slowly progressive
neurodegenerative disease that is primarily characterized by the
loss of dopaminergic (DAergic) neurons in several dopaminergic
networks, most intensively in the ventral tier of the substantia
nigra pars compacta (SNpc) within the mesostriatal/nigrostriatal
pathway (Koller, 2003; Pereira and Aziz, 2006; Cummins and
Barker, 2012; Teixeira et al., 2013). The depletion of SN neurons
leads to the loss of DAergic innervations and consequently
to striatal DA deficiency, which is responsible for the major
sensory-motor symptoms of PD (Dauer and Przedborski,
2003).
A considerable body of evidence has revealed the potential
of MSCs to promote protection and/or recovery of DAergic
neurons against neurotoxin-induced nigrostriatal degeneration.
Indeed, several studies have demonstrated that BMSCs secretome
protect and/or regenerate DAergic neurons in in vitro and
in vivo models of PD, through the secretion of growth
factors and cytokines (summarized in Table 2; Weiss et al.,
2006; Shintani et al., 2007; McCoy et al., 2008; Kim et al.,
2009; Sadan et al., 2009; Blandini et al., 2010; Cova et al.,
2010; Wang et al., 2010; Danielyan et al., 2011; Park et al.,
2012). For instance, Shintani and coworkers demonstrated
that BMSCs conditioned media (CM) was able to promote
survival of tyrosine hydroxylase (TH)-positive DAergic neurons
in rat primary cultures of ventral mesencephalic cells (Shintani
et al., 2007). Moreover, intrastriatal transplantation of fetal
mesencephalic cells treated with human BMSCs CM, during
steps of donor preparation and implantation, induced survival
of DAergic grafted cells and promoted functional recovery
in a 6-OHDA rat model of PD (Shintani et al., 2007). The
observed protection of DAergic neurons was attributed to
BMSCs secretion of BDNF, GDNF and bFGF. Similarly, Sadan
et al. showed that human BMSCs (hBMSCs) cultured in the
presence of growth factors, not only significantly increased the
viability of the SH-SY5Y neuroblastoma cell line exposed to
6-OHDA, but also that BMSCs transplanted into the striatum
of a 6-OHDA rat model of PD, migrated to the lesion site,
and increased the numbers of TH-positive cells and DA
levels (Sadan et al., 2009). These neuroprotective and neuro-
regenerative effects were accompanied by an improvement in
animals’ motor behavior and were correlated with BMSCs
secretion of BDNF and GDNF. This expression pattern is in
accordance with data published by Blandini and co-workers
using the same animal model (Blandini et al., 2010). On
the other hand, Wang and colleagues associated rat-derived
BMSCs expression of stromal cell-derived factor 1 (SDF)-
1α with the DAergic neurons protection against 6-OHDA
neurotoxin both in vitro and in vivo, through anti-apoptotic
based mechanisms (Wang et al., 2010). Moreover, Cova et al.
TABLE 2 | Summary of the studies focused on the impact of MSCs on multiple aspects of PD regenerative medicine.
Reference Outcomes
Weiss et al. (2006) • Transplantation of MSCs isolated from the Wharton Jelly into a 6-OHDA rat model led to behavioral
improvements and a local increase of GDNF.
Shintani et al. (2007) • CM of BMSCs promoted survival of TH+ neurons;
• Transplantation of fetal mesencephalic cells treated with BMSCs CM promoted functional
recovery in a 6-OHDA rat model.
Sadan et al. (2009) • BMSCs transplantation into a 6-OHDA rat model led to increased TH+ cells and tissue DA levels;
• Data correlated with secretion of GDNF by BMSCs.
Wang et al. (2010) • BMSCs protected DA neuronal apoptotic cell death through SDF-1α.
Cova et al. (2010) • Long term survival of BMSCs upon transplantation into the striatum;
• Increased neurogenesis in SVZ;
• Survival of DAergic terminal.
Danielyan et al. (2011) • Intranasal delivery of BMSCs in a 6-OHDA rat model reduced the levels of pro-inflammatory
cytokines.
OHDA, Hydroxidopamine; GDNF, Glial Derived Neurotrophic Factor; TH, Tyrosine Hydroxylase; CM, Conditioned Media; DA, Dopamine; SDF, Stromal Cell Derived Factor;
SVZ, Subventricular Zone.
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demonstrated that BMSCs transplanted in the striatum of
a 6-OHDA rodent model of PD were able to survive and
interact with the lesion site surroundings, thus enhancing
the survival of DAergic terminals and neurogenesis in the
SVZ in a sustained manner (Cova et al., 2010). Finally,
the secretion of BDNF in vivo by BMSCs, was correlated
with the activation of endogenous stem cells (Cova et al.,
2010).
In addition to the capability of BMSCs to induce survival
of DAergic neurons, its effects have also been related with
their immunomodulatory properties. In this context, intranasally
delivered rat BMSCs into 6-OHDA hemi-parkinsonian rats
migrated toward the SN and the striatum and reduced the overall
expression of pro-inflammatory cytokines, such as IL-1β, IL-2;
IL-12; tumor necrosis factor alpha (TNF-α) and interferon γ
(INF γ). Moreover, their presence also revert the loss of nigral
DAergic neurons and striatal fibers (Danielyan et al., 2011).
From the above-referred studies, it is clear that there is
increasing evidence indicating that the neuroprotective and
neuroregenerative effects of MSCs observed in PD are attributed
to the secretion of soluble growth factors and cytokines. The
secretion of these factors by MSCs not only protects DAergic
neurons from further degeneration and enhances endogenous
restorative processes (e.g., neurogenesis), but also acts as
inflammation and immune response modulators. Moreover,
recent reports have shown that besides soluble growth factors
and cytokines, MSCs also secrete microvesicles and exosomes
containing mRNAs and/or miRNAs (microRNAs), which are
believed to mediate cell-to-cell communication and act as
reparative agents (Baglio et al., 2012). Indeed exosomes secreted
by BMSCs in vitro not only mediate communication with
neurons and astrocytes, but also regulate neurite outgrowth
by transfer of miRNA (miR-133b) to neural cells (Xin et al.,
2012).
Ischemic Stroke (IS)
Cerebrovascular diseases, such as stroke, result from blood vessel
occlusion or damage, leading to focal tissue loss and death of
endothelial cells and multiple neural populations (Lindvall and
Björklund, 2004; Lindvall and Kokaia, 2010).
It has been proposed that the transplantation of MSCs
(summarized in Table 3) can represent a feasible therapeutic
option for IS (Locatelli et al., 2009). Indeed, studies have
shown that after intravenous administration of BM-MSCs, these
have the capacity to migrate to the lesion site promoting
tissue regeneration and behavioral improvement (Komatsu
et al., 2010). Moreover, these cells were able to promote
neurogenesis, increase the survival of neuroblasts and to reduce
the volume of lesion after IS (Keimpema et al., 2009; Zheng
et al., 2010). According to Wakabayashi and colleagues the
secretion of molecules such as IGF-1, VEGF, EGF, BNDF
and bFGF mediate some of the observed effects, namely the
reduction of lesion size and the modulation of the inflammatory
environment for host cells (Wakabayashi et al., 2010). Leu
et al. (2010) also proposed that like BM-MSCs, adipose
stroma/stem cells (ASCs) therapy also enhances angiogenic
and neurogenic processes. Although the exact mechanism of
these cells remains still unclear, other studies have suggested
that homing properties, cytokines (SDF-1α, IL-1, IL-8) effects,
and paracrine mediators (HGF, BDNF, IGF-1, VEGF) could
pinpoint ASCs effects, contributing to tissue regeneration
and functional behavior (Tang et al., 2005; Banas et al.,
2008; Chen et al., 2008a). On the other hand Koh et al.
(2008) also demonstrated that MSCs exhibited a migratory
tropism to the lesion site, which might foster the creation
of new networks between the host neural and transplanted
stem cells (Koh et al., 2008). Additionally exosomes secreted
by MSCs were also shown to mediate important actions in
these environments. Xin et al. (2013b) suggested that the
observed improvements were due to the presence of miRNA-
133b in the exosomal fraction of MSCs that were transplanted
into a middle cerebral artery occlusion (MCAo) rat model.
Similarly, the same authors also demonstrated that after systemic
administration of MSCs-derived exosomes, there was an increase
in neurovascular plasticity, which led to an enhancement of the
functional recovery of an animal model of stroke (Xin et al.,
2013a,b).
Glioblastoma Multiforme (GBM)
Malignant gliomas are particularly dramatic cancers of the
CNS, ranking first among all human tumor types for tumor-
related average years of life lost (Burnet et al., 2005). GBM is
the most common and most malignant subtype (Ohgaki and
Kleihues, 2007), typically treated with surgery, radiotherapy and
temozolomide (TMZ)-based chemotherapy (Stupp et al., 2005).
Despite this multimodal approach, virtually all GBMs eventually
recur and are fatal. GBMs present critical hallmark features
that largely contribute to treatment failure, including their high
invasive capacity, the presence of the bood-brain barrier, and
remarkable genetic and epigenetic heterogeneity. Additionally,
GBMs present a small population of cells with neural stem cell-
like properties (Singh et al., 2003), called glioma stem cells (GSC),
which display remarkable features in the context of glioma
pathophysiology, including self-renewal capacity (generating
both GSCs and non-GSCs cancer cells necessary for tumor
maintenance), multipotency (differentiating into diverse cell
population lineages), and prominent tumorigenic potential in
vivo. In resemblance with NSCs that are located in specific
highly-vascularized neurogenic niches of the adult brain, GSCs
also accumulate and depend on the prominent vasculature
of these regions to control their stemness and differentiation
processes (Folkins et al., 2007; Calabrese et al., 2007; Gilbertson
and Rich, 2007; Hadjipanayis and van Meir, 2009). GSCs
have been shown to be more resistant to radiation and
conventional chemotherapeutic drugs, and are believed to be
responsible for tumor relapse observed almost universally in
GBM patients (Singh et al., 2003; Bao et al., 2006; Calabrese
et al., 2007; Chalmers, 2007). Since the clinical prognosis
of GBM patients has not improved significantly in the last
years, it is urgent to develop novel unconventional therapeutic
strategies.
Like in other cancer types, a relatively new and promising
therapeutic approach to tackle malignant gliomas is based on
the use of (normal) stem cells. The most unique and critical
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TABLE 3 | Impact of MSCs administration on ischemic stroke related animal models.
Reference Outcomes
Koh et al. (2008) • MSCs exhibited migratory tropism to injury sites.
Komatsu et al. (2010) • Intravenous delivery of MSCs promoted tissue regeneration and behavioral improvement.
Keimpema et al. (2009); • Reduction of the volume of the injury after IS;
Zheng et al., 2010 • Increased levels of neurogenesis;
• Survival of neuroblasts.
Wakabayashi et al. (2010) • Reduction of the injury size and modulation of the inflammatory environment through the secretion
of IGF-1, VEGF, EGF, BNDF and bFGF.
Leu et al. (2010) • ASCs based therapies enhanced angiogenic and neurogenic processes in IS models.
Xin et al. (2013a) • Systemic administration of exosomal fraction of the secretome impacted neurovascular plasticity.
IGF, Insulin Growth Factor; VEGF, Vascular Endothelial Growth Factor; EGF, Epidermal Growth Factor; BDNF, Brain Derived Neurotrophic Factor; bFGF, basic Fibroblast
Growth Factor; ASCs, Adipose Tissue Stem Cells.
feature of stem cells that renders them as attractive tools for
cancer therapy is their intrinsic capacity to migrate towards
pathologic tissues, including malignant tumors. Indeed, this
selective cancer-tropism has been shown for various stem
cell types, including embryonic, hematopoietic, mesenchymal,
neural, endothelial, and experimentally-induced stem cells (e.g.,
inducible pluripotent stem cells, iPSCs; Stuckey and Shah,
2014). Whether this innate tropism of normal stem cells is
associated with cancer promotion or suppression functions
is still controversial and a matter of debate, particularly in
the case of MSCs, as reported by contradicting findings
in many studies (Klopp et al., 2011). Nonetheless, it is
widely consensual that the rational engineering of stem
cells to express or deliver anticancer therapeutic agents,
while taking advantage of their innate tumor tropism and
immunosuppressive properties, may be a promising strategy to
target cancer.
Aboody et al. (2000) first showed that NSCs are able
to migrate towards the major tumor site and track along
with invading glioma cells that form small satellite tumor
masses (Aboody et al., 2000). Importantly, this tumor-tropism
by NSCs was also later observed towards brain metastasis
derived from breast cancer (Joo et al., 2009) and melanoma
(Aboody et al., 2006), highlighting the potential application
of NSCs as therapeutic vehicles for primary and metastatic
brain tumors. In this context, and because stem cells are
relatively easy to be genetically modified, many studies have
explored them as cargo delivery vehicles for therapeutic
agents, including cytokines, pro-drug converting enzymes,
oncolytic viruses, nanoparticles, and antibodies, as summarized
below.
Cytokines
Many recent studies have explored NSCs as efficient delivery
systems of soluble tumor necrosis factor-related apoptosis-
inducing ligand (sTRAIL), a cytokine that promotes apoptosis
by binding to death receptors commonly present in the cellular
membrane of tumor cells. These engineered NSCs can track
tumor cells and deliver sTRAIL to glioma cells in vivo, resulting
in significant anti-tumor effects. Combinations of sTRAIL-
secreting NSCs with anticancer drugs, including bortezomib (a
proteasome inhibitor), PI-103 (a dual PI3K/mTOR inhibitor),
and lanatoside C (a cardiac glycoside), resulted in synergistic
therapeutic effects, emphasizing the potential clinical value
of sensitizing glioma cells to TRAIL-induced NSC-mediated
cell death (Hingtgen et al., 2010; Bagci-Onder et al., 2011;
Balyasnikova et al., 2011; Teng et al., 2014). Importantly,
studies with MSCs engineered to deliver sTRAIL showed
equally promising results, as these cells efficiently tracked and
successfully induced a caspase-dependent cell death in glioma
cells, resulting in increased survival of glioma mice models (Shah
et al., 2004; Menon et al., 2009; Sasportas et al., 2009; Choi et al.,
2011).
NSCs have also been genetically modified to express and
secrete IL-12, a cytokine that does not act directly in tumor cells,
but is involved in the enhancement of T-cell-mediated antitumor
immune responses. Using intracranial glioma mice models,
Ehtesham et al. showed that IL-12-secreting NSCs injected
directly in the tumor significantly prolong the survival of mice
(Ehtesham et al., 2002). Similarly, MSCs genetically engineered
to express a modified IL-12 also prolonged the survival of glioma
mice models when injected intratumorally (Ryu et al., 2011).
Similar approaches were used to engineer NSCs, MSCs, and
bone marrow-derived stem cells to produce pro-inflammatory
cytokines, including IL-4, IL-7, IL-23, and IFN-β, which were
shown to increase the infiltration of anti-tumor T-cells and
natural killer (NK)-cells in glioma murine models (Benedetti
et al., 2000; Nakamizo et al., 2005; Yuan et al., 2006; Gunnarsson
et al., 2010). These studies provide important proof-of-concept
on the potential of modulating immune mediators with different
types of stem cells in order to achieve increased therapeutic
responses.
Enzymes/pro-drugs
Another novel approach involves the modification of stem
cells to express enzymes that convert inactive pro-drugs into
toxic compounds, in order to increase tumor tissue selectivity.
One of the most popular pro-drug/enzyme therapeutic systems
is the herpes simplex virus type 1 thymidine kinase (HSV-
tk) in combination with the pro-drug ganciclovir (GCV),
based on the HSV-tk-mediated phosphorylation of inert GCV
into a cytotoxic product that kills HSV-tk-positive cells and
neighboring cells (via the so-called bystander effect). Taking
advantage of the tumor-tropism of stem cells, many recent
studies have explored the incorporation of HSV-tk into NSCs,
MSCs, and bone marrow-derived progenitor cells as therapeutic
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strategies for glioma, showing promising results (Li et al., 2005;
Uhl et al., 2005; Miletic et al., 2007; Uchibori et al., 2009;
Matuskova et al., 2010). Other enzyme/pro-drug systems that
have been explored as anti-cancer therapeutic tools for stem cells
include the cytosine deaminase (CD), which converts inactive 5-
fluorocytosine (5-FC) into the cytotoxic 5-fluorouracil (5-FU),
and the rabbit carboxylesterase enzyme (rCE), which converts the
pro-drug CTP-11 (irinotecan) into the anticancer topoisomerase
I inhibitor SN-38 (7-ethyl-10-hydroxycamptothecin). These
approaches have been tested with promising therapeutic results
in stem cells of different origin (NSCs and MSCs) and distinct
glioma models (including rat and mice models), either alone
or in combination with other anticancer drugs (Aboody et al.,
2000, 2006; Lim et al., 2011; Yin et al., 2011; Choi et al.,
2012; Fei et al., 2012; Kim et al., 2012; Kosaka et al., 2012;
Ryu et al., 2012; Zhao et al., 2012), emphasizing the potential
of these enzyme/pro-drug systems as stem cell-mediated anti-
tumor therapies.
Oncolytic viruses
The use of oncolytic viruses as therapeutic agents has been
extensively studied for cancer, taking advantage of their
capacity to infect, replicate within, and ultimately kill cancer
cells. Despite many promising pre-clinical studies, including
in gliomas (Wollmann et al., 2012), the clinical application
of oncolytic viruses presents critical obstacles, including sub-
optimal distribution throughout the major tumor cores and
particularly to invading cancer cells, low infection rates, and
host anti-viral immune responses (Yamamoto and Curiel, 2010).
Critically, these shortcomings can be largely surpassed by the
incorporation of oncolytic viruses within tumor-trophic stem
cells. Indeed, recent work has been performed in NSCs, MSCs
and ASCs that were used as oncolytic viral carriers to treat in
vivo models of glioma, showing that these cells retain tumor-
tropism, permit continued viral replication for several days, and
cause glioma cell death in vivomore efficiently than viral delivery
alone (Herrlinger et al., 2000; Sonabend et al., 2008; Tyler et al.,
2009; Yong et al., 2009; Josiah et al., 2010; Ahmed et al., 2011;
Thaci et al., 2012).
Nanoparticles and antibodies
In the last 4 years, some studies also started to explore MSCs as
delivery vehicles of drug-loaded nanoparticles and antibodies to
target glioma. This strategy aims to improve the capacity of these
agents to cross the blood-brain barrier, while minimizing toxic
side effects caused by intravenous administrations. The results
obtained to date indicate that these cells can successfully deliver
nanoparticles (e.g., lipid nanocapsules loaded with ferrociphenol
and membrane-anchored silica nanorattle–doxorubicin) and
antibodies (e.g., cell surface-bound single-chain anti-EGFRvIII)
to glioma cells in vivo, resulting in increased anti-tumor
responses (Balyasnikova et al., 2010; Roger et al., 2010, 2012; Li
et al., 2011).
In conclusion, a wide variety of stem cells hold great promise
as novel therapeutic tools for the treatment of therapy-insensitive
malignant brain gliomas. Some hallmarks of these cells that
are critical for this purpose include their high tumor-trophic
migration and tracking capacity, peculiar immunosuppressive
properties, and easy genetic manipulation for cargo delivery.
Nonetheless, inherently to its innovative nature and similarly
to other experimental glioma therapies attempted in the past,
several issues will certainly need to be addressed in order to
translate these promising pre-clinical findings into clinically-
relevant therapies for patients. Some of the obstacles that
may be envisaged include the proper selection of the best
stem cell type/origin, choice of the most appropriate cargo
for each tumor type or personalized to specific patients,
optimization of administration routes and dosing, evaluation
of the long-term cell fate of engrafted stem cells (which
may conceptually also form tumors or differentiate aberrantly
in the target tissue/organ), and development of real-time
imaging systems for therapeutic stem cells in vivo. The recent
literature on this topic is very promising, but a concerted and
integrated effort in this field will still be crucial to definitely
pave the way to better treat patients, most likely integrating
the rational use of particular stem cell-based approaches
to act synergistically in concert with surgery, radiation and
chemotherapy.
Conclusion
It is now evident that cells derived from the osteogenic and
neurogenic niches present important interactions that may
impact the future development of CNS related therapies. As
discussed in the present review there is robust evidence showing
that MSCs and their secretome are able to modulate the action
of neurogenic niches and neural progenitors. Their usage was
shown to promote the functional recovery of animal models of
PD and stroke, as well as the application of novel paradigms
for glioblastoma therapies. Nevertheless, it is still a largely
unexplored field, with many questions yet to be addressed.
For instance, are the traditional growth factors the main
mediators of the actions promoted by the MSCs secretome; or,
instead, do MSCs-derived unknown neuroregulatory molecules
modulate such actions? Can we modulate the tropism that
these cells display towards gliobastomas? So far, most of the
studies focused on the action of MSCs towards the neurogenic
niches, namely NSCs. However, few address if and how the
neurogenic niches, and within them NSCs, modulate the action
of MSCs. In fact a bidirectional communication between both
cell types is most likely to occur. The answer to this and
other questions will be important to further define this field
in the future, and its impact in future CNS regenerative
strategies.
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